MedTrace Logo

Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)

NCT03055741 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2019-08-20

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of DHP1401 in patients with mild-moderate Alzheimer's disease treated with donepezil

Conditions

  • Mild-moderate Alzheimer's Disease

Interventions

DRUG

Donepezil

5mg or 10mg, once a day, 24 weeks

DRUG

DHP1401

Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks

DRUG

Placebo

Placebo was administrated in two divided dosed a day for 24 weeks

Sponsors & Collaborators

  • Daehwa Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Seol Heui Han, M.D., Ph.D · Konkuk University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-28
Primary Completion
2019-02-28
Completion
2019-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03055741 on ClinicalTrials.gov